tiprankstipranks
Daewoong Pharmaceutical Co., Ltd. (KR:069620)
:069620
South Korea Market
069620
Daewoong Pharmaceutical Co., Ltd.
RESEARCH TOOLSreports

Daewoong Pharmaceutical Co., Ltd. (069620) Financial Statements

― Followers

Daewoong Pharmaceutical Co., Ltd. Financial Overview

Daewoong Pharmaceutical Co., Ltd.'s market cap is currently ₩1.29T. The company's EPS TTM is $16988.79; its P/E ratio is 6.59; and it has a dividend yield of 0.54%. Daewoong Pharmaceutical Co., Ltd. is scheduled to report earnings on August 14, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue₩ 1.57T₩ 1.42T₩ 1.38T₩ 1.28T₩ 1.15T
Gross Profit₩ 812.85B₩ 734.17B₩ 687.11B₩ 638.96B₩ 544.75B
Operating Income₩ 195.51B₩ 147.94B₩ 121.12B₩ 95.80B₩ 88.73B
EBITDA₩ 245.78B₩ 112.52B₩ 164.91B₩ 85.12B₩ 69.07B
Net Income₩ 195.86B₩ 24.73B₩ 121.74B₩ 42.24B₩ 24.51B
Balance Sheet
Cash & Short-Term Investments₩ 172.80B₩ 116.35B₩ 137.68B₩ 140.65B₩ 173.73B
Total Assets₩ 2.36T₩ 1.98T₩ 1.77T₩ 1.56T₩ 1.42T
Total Debt₩ 829.39B₩ 649.25B₩ 469.69B₩ 446.71B₩ 445.70B
Net Debt₩ 660.45B₩ 546.30B₩ 358.18B₩ 343.76B₩ 369.79B
Total Liabilities₩ 1.23T₩ 1.05T₩ 858.03B₩ 822.12B₩ 712.77B
Stockholders' Equity₩ 1.01T₩ 794.64B₩ 767.30B₩ 608.02B₩ 573.57B
Cash Flow
Free Cash Flow₩ -42.33B₩ -177.51B₩ 26.67B₩ 4.91B₩ -34.80B
Operating Cash Flow₩ 149.21B₩ 51.49B₩ 136.01B₩ 118.21B₩ 39.99B
Investing Cash Flow₩ -247.36B₩ -265.45B₩ -165.62B₩ -106.87B₩ -87.68B
Financing Cash Flow₩ 164.69B₩ 200.62B₩ 39.22B₩ 15.52B₩ 50.22B
Currency in KRW

Daewoong Pharmaceutical Co., Ltd. Earnings and Revenue History

Income Statement >

Daewoong Pharmaceutical Co., Ltd. Debt to Assets

Balance Sheet >

Daewoong Pharmaceutical Co., Ltd. Cash Flow

Cash Flow >

Daewoong Pharmaceutical Co., Ltd. Forecast EPS vs Actual EPS

Earnings >